Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update

Area of Science:

• Immunology
• Oncology
• Hepatology

Background:

• Hepatocellular carcinoma (HCC) remains a significant health challenge, with limited effective treatment options.
• Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 are emerging as a promising therapeutic strategy.
• Current research focuses on optimizing the use of these inhibitors as monotherapy or in combination for HCC treatment.

Purpose of the Study:

• To evaluate the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.
• To explore combination therapies involving anti-PD-L1 and anti-CTLA-4 antibodies.
• To investigate novel therapeutic combinations for HCC, including molecular targeted agents.

Main Methods:

• Clinical trials assessing PD-1, PD-L1, and CTLA-4 antibodies in HCC patients.
• Presentation of results from combination therapy with durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) at ASCO 2017.
• Nonclinical studies evaluating the combination of pembrolizumab and lenvatinib.

Main Results:

• Encouraging response rates of 25% overall and 40% in uninfected patients with durvalumab and tremelimumab combination therapy.
• Transcatheter arterial chemoembolization and radiofrequency ablation can enhance tumor immunogenicity.
• Pembrolizumab and lenvatinib combination therapy demonstrated inhibition of immunosuppressive factors and activation of anti-cancer immunity.

Conclusions:

• Combination immunotherapy, such as anti-PD-L1 and anti-CTLA-4, shows potential in treating HCC.
• Local therapies can be combined with immune checkpoint inhibitors to improve outcomes.
• Further research is needed to identify optimal molecular targeted agents for combination with immune checkpoint inhibitors in HCC.